期刊
HAEMATOLOGICA
卷 92, 期 7, 页码 970-973出版社
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.11172
关键词
standardization; quantitative PCR; BCR-ABL; chronic myelogenous leukemia
类别
资金
- Novartis Pharma, Nurnberg, Germany
- Qiagen, Hilden, Germany
- Competence Network 'Acute and chronic leukemias' - German Bundesministerium fur Bildung und Forschung (Projekttrager Gesundheitsforschung
- DLR e.V.) [01 GI9980/6]
- European LeukemiaNet within the 6th European Community Framework Programme for Research and Technological Development
Due to the lack of comparability of BCR-ABL mRNA quantification results generated by various methodologies in different laboratories, an international multicenter trial was started with the participation of six laboratories (platforms: LightCycler (TM), LC, n=3; TaqMan (TM), TM, n=3). One hundred and eighty-six PB samples derived from healthy donors were spiked with serial dilutions (1:20 to 1:2x10(6)) of b2a2, b3a2 or e1a2 BCR-ABL positive white blood cells (WBC) from leukemic patients. After PAXgene (TM) stabilization, blinding, freezing and distribution, standardized RNA extraction, cDNA synthesis, PCR protocols and data evaluation were carried out. There was no significant difference in the results achieved using LC and TM technologies, but a considerable overall variation (CV=0.74 for ratios BCR-ABL/ABL). Up to a dilution of 1:1,000, 27/30 of the 2.5 mL samples tested positive. For higher dilutions, a PB volume of 5 or 10 ml was required to improve sensitivity. The study showed the feasibility of RQ-PCR standardization independent of the PCR machine used.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据